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Abstract 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, characterised by 
progressive loss of cognition. Over 35 million people are currently diagnosed with AD worldwide. 
Unfortunately, current therapies are limited to very modest symptomatic relief. Brains of AD patients 
are characterised by deposition of amyloid-β (Aβ) and hyperphosphorylated forms of tau protein. AD 
brains also exhibit neurodegeneration and show high levels of oxidative stress and inflammation. The 
phytocannabinoid cannabidiol (CBD) possesses neuroprotective, anti-oxidant, and anti-inflammatory 
properties and reduces Aβ production and tau hyperphosphorylation in vitro. CBD has also been shown 
to be effective in vivo making the phytocannabinoid an interesting candidate for novel therapeutic 
interventions in AD, especially as it lacks psychoactive or cognition-impairing properties. CBD 
treatment would be in line with preventative, multimodal drug strategies targeting a combination of 
pathological symptoms, which might be ideal for AD therapy. Thus, this review will give a brief 
introduction to AD biology and current treatment options before outlining comprehensively CBD 
biology and pharmacology followed by in vitro and in vivo evidence for CBD’s therapeurtic potential. 
We will also discuss the role of the endocannabinioid system in AD before commenting on the 
potential future of CBD for AD therapy (including safety aspects). 
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2-AG: 2-arachidonylglycerol (endocannabinoid) 
2-LG: 2-linoleoylglycerol 
5-HT: 5-hydroxytryptamine / serotonin 
5-HT1A: serotonergic 5-hydroxytryptamine 1A receptor 
A2A: adenosine 2A receptor 
Aβ: beta-amyloid protein; majority of Aβ is 40 residues in length (Aβ40), whereas approximately 10% 
form the 42 residue-length variant (Aβ42) 
ABHD6: Serine hydrolase alpha/beta-hydrolase domain-containing 6 
ACEA: arachidonyl-20-chloroethylamide (CB1 agonist) 
AICD: amyloid precursor protein intracellular domain 
AEA: anandamide (also called Ν-arachidonoylethanolamine) 
AMPA: 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid 
APP: amyloid precursor protein 
ATP: adenosine triphosphate 
BDNF: brain-derived neurotrophic factor 
Ca2+: calcium ions 
CB1: cannabinoid receptor 1 
CB2: cannabinoid receptor 2 
CBD: cannabidiol (phytocannabinoid) 
CGS-21680: A2A receptor agonist 
CNS: central nervous system 
COX-2: cyclooxygenase 2 
CP 55,940: synthetic cannabinoid, full agonist of CB1 and CB2 (>40 more potent than THC) 
CSF: cerebrospinal fluid 
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DAGL-α/β: diacylglycerol lipases α/β 
Dronabinol: pharmaceutical formulation of THC 
DNA: deoxyribonucleic acid 
18FDG: 18F-fluoro-deoxyglucose  
FAAH: fatty acid amide hydrolase 
GABA: γ-aminobutyric acid 
GFAP: glial fibrillary acidic protein 
GPR18 / GPR55 / GPR118: G-protein coupled receptors 18, 55, and 119 
GSK3-β: glycogen synthase kinase 3 β 
GW9662: peroxisome proliferator-activated receptor γ antagonist 
HU-308: synthetic cananbiniod; selective CB2 agonist 
Iba1: ionised calcium binding adaptor molecule 1 (i.e. a microglia/macrophage-specific calcium-
binding protein) 




JWH-133: synthetic cannabinoid selective for CB2 
MDA7: 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl) carbonyl) piperidine - a novel highly 
selective CB2 agonist 
MAGL: monoacylglycerol lipase 
Nabilone: synthetic cannabinoid mimicking the effects of THC 
NAPE-PLD: N-acyl phosphatidylethanolamine-selective phospholipase D 
NMDA: N-methyl-D-aspartate 
NF-ĸB: transcription factor nuclear factor ĸB 
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NFT: neurofibrillarly tangle 
NO: nitric oxide 
iNOS: inducible nitric oxide synthase 
p-GSK3β: phosphorylated glycogen synthase kinase 3 β 
p38 MAP kinase: p38 mitogen-associated protein kinase 
PEA: palmitoylethanolamide 
PET: positron emission tomography 
PND: Postnatal day 
PPARγ: peroxisome proliferator-activated receptor γ 
PS1: presenilin 1 
PS2: presenlin 2 
ROS: reactive oxygen species 
Sativex®: mixture of a THC botanical extract (containing 67.1% THC, 0.3% CBD, 0.9% cannabigerol, 
0.9% cannabichromene, and 1.9% other phytocannabinoids) and a CBD botanical extract (containing 
64.8% CBD, 2.3% THC, 1.1% cannabigerol, 3.0% cannabichromene, and 1.5% other 
phytocannabinoids), developed/produced by GW Pharmaceuticals Ltd (Cambridge, UK) in a 1:1 
proportion 
SAPK/JNK: stress-activated protein kinase/c-Jun NH(2)-terminal kinase 
SR141716: CB1 antagonist  
SR144528: CB2 antagonist  
SOD1/2: superoxide dismutase 1/2 
THC: Δ9-tetrahydrocannabinol (phytocannabinoid) 
TNF-α: tumor necrosis factor-alpha 
HU-210: synthetic cannabinoid selective for CB1 (100-800 times more potent than THC) 
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VR1: vanilloid receptor type 1; also known as the transient receptor potential cation channel subfamily 
V member 1 (TRPV1) 
VR2: vanilloid receptor type 2 
WIN 55,212-2: synthetic cannabinoid with mixed CB1/CB2 agonism (similar to THC) 




1. Alzheimer’s disease 
As the world’s population ages and life expectancy increases, many individuals are faced with an 
increased risk of developing dementia. Dementia is the severe loss of cognitive abilities that is not part 
of the normal ageing process and currently, over 46 million people globally are living with dementia 
(World Alzheimer Report 2015; (Ferri et al., 2005)). The most prominent form of dementia is 
Alzheimer’s disease (AD), which is predicted to affect 1 in 85 people globally by the year 2050. AD is 
categorised by three progressive clinical stages: mild, moderate and severe (Zandi et al., 2002). The 
mild stage is characterised by short-term memory loss, subtle difficulties in learning and 
communication as well as spatial disorientation. During the moderate stage, memory decline (e.g. 
noticeable lapses in short-term memory and loss of reading and writing ability) begins to affect 
everyday tasks resulting in increased frustration and loss of emotional control. In the severe stage, AD 
patients face a universal disruption of cognitive abilities including severely impaired learning and 
speech, inability to recognise familiar people and loss of control over bodily functions. Eventually, 
individuals are left in a weakened physical state where they are prone to other illnesses (e.g. 
infections).  
 
1.1 Biology of Alzheimer’s disease 
AD is characterised as either sporadic (late-onset) or familial (early onset, autosomal dominant). 
Sporadic AD is the most common and least understood form of AD, accounting for up to 95% of 
reported AD cases (Gotz and Ittner, 2008). The age of onset for sporadic AD is usually around 65 
years. The cause of sporadic AD remains to be elucidated, but is believed to result from a complex 
interaction of various environmental risk factors and multiple susceptibility genes (Kamboh, 2004). A 
great deal of information has been gained from the analysis of genetic risk factors. APOE genotype is 
by far the most robust predictor of AD risk with the ε4 allele affording increased risk and the ε2 allele 
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affording protection as compared to the most common ε3 allele (Corder et al., 1993). Genome-wide 
association studies (GWAS) studies have confirmed the importance of APOE in AD risk and also 
identified several additional genetic risk factors, many of which are, like APOE, related to lipid 
homeostasis (e.g. GAB2) (Belbin et al., 2011).  
Familial AD is autosomal dominant and accounts for <10% of cases, with an earlier age of onset than 
the sporadic form, and often occurring at 40-50 years of age. Familial AD is linked to mutations in the 
amyloid precursor protein gene (APP) or in genes encoding presenilin 1 (PS1) and presenilin 2 (PS2). 
Mutations in PS1 or PS2 cause the most common and aggressive forms of familial AD and are 
responsible for the activity of γ-secretase, one of the enzymes responsible for the cleavage of APP into 
β-amyloid peptides (Aβ). Aβ peptides are found in human brains and have an important damaging 
pathological function in AD. However, they are also involved in several other processes, including the 
regulation of cholesterol transport, antioxidant, and anti-microbial properties (Baruch-Suchodolsky and 
Fischer, 2009, Soscia et al., 2010, Umeda et al., 2010). They possess high turnover rates and are 
associated with synaptic vesicle release, implying a role in neurotransmission (Marchesi, 2011). 
APP is cleaved and processed by α-, β- and γ-secretases via two pathways, a non-amyloidogenic and an 
amyloidogenic pathway. The non-amyloidogenic pathway accounts for the majority of APP processing 
in the healthy brain whereby APP is cleaved by α-secretase to generate: 1) a soluble N-terminal 
fragment (sAPPα), which has neuroprotective properties; 2) a C-terminal fragment (CTFα), that is 
retained in the membrane and processed further by γ-secretase to yield an N-terminal fragment (p3); 
and, 3) a membrane-bound C-terminal fragment, the APP intracellular domain (AICD), which regulates 
gene transcription. A minority of APP is processed by the amyloidogenic pathway, leading to the 
generation of Aβ: first, β-secretase cleaves APP resulting in soluble APP and a cell-membrane bound 
fragment; second, γ-secretase cleaves this fragment further, producing Aβ and AICD. Importantly, the 
majority of Aβ produced are 40 residues in length (Aβ40), whereas approximately 10% form the 42 
residue-length variant (Aβ42). Aβ42 is the longer, more hydrophobic isoform that is more prone to fibril 
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formation, and therefore found predominantly in cerebral plaques. Mutations in APP or the genes for 
the APP-processing enzymes presenilin 1 or presenilin 2 appear to influence the overproduction of 
Aβ42. The excessive production of Aβ42 increases its aggregation in extracellular deposits that form 
amyloid or senile plaques, one of the two distinct types of lesions observed post-mortem in brains of 
AD patients. 
The second pathological hallmark of AD is the intracellular accumulation and hyperphosphorylation of 
microtubule-associated protein tau (MAPT), which leads to the formation of neurofibrillary tangles 
(NFT). Tau is predominantly found in axons of neurons, where it promotes the assembly of 
microtubules from tubulin, stabilises them, and supports microtubule-dependent axonal transport of 
organelles and biomolecules. In the healthy brain, 2-3 amino acid residues on tau are phosphorylated, 
whereas in AD, tau proteins are hyperphosphorylated (average of 9 phosphates per molecule), leading 
to lowered tau affinity for microtubules, increased tau resistance to calcium-activated neutral proteases 
and finally the aggregation and formation of NFTs (Lie et al., 2005). However, so far, no tau mutations 
have been linked to AD (Andorfer et al., 2003, Wolfe, 2009, Armstrong, 2013).   
The presence of elevated Aβ in the brain is strongly correlated with cognitive decline in patients 
diagnosed with early dementia (Naslund et al., 2000) and this has been confirmed using transgenic AD 
mouse models that routinely express mutant forms of APP and PS1 (Hsiao et al., 1996, Holcomb et al., 
1998). However, other preclinical data argue against a direct correlation of amyloid plaque load with 
cognitive abilities in AD mouse models suggesting that that amyloid plaques might not be the cause of 
AD but rather a consequence of pathologic changes in brain metabolism (Stumm et al., 2013). It has 
been hypothesised that deposits of Aβ are responsible for causing and exacerbating tau 
hyperphosphorylation and the generation of NFTs, as Aβ depositions have been found prior to any 
signs of tau pathology (Gotz et al., 2001). Accumulation of tau and the associated NFTs induce 
cognitive deficits, which correlate with neurodegeneration. Transgenic mouse models expressing tau 
mutations demonstrate cognitive deficits and AD-relevant pathology (Barten et al., 2012). These 
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processes eventually lead to neuronal death and ultimately dementia (amyloid cascade hypothesis). In 
humans, extensive tau pathology is generally associated with later stages of AD, but changes in tau 
biology could potentially also occur much earlier (Kuret et al., 2005). Some researchers argue that tau 
pathology correlates best with AD progression (Gotz et al., 2008). 
An additional hypothesis regarding the role of Aβ in AD suggests that resting microglia become 
activated in response to the presence of Aβ and cluster at sites of amyloid deposition in the brain. This 
initiates neuroinflammatory processes and the release of neurotoxic factors (e.g. pro-inflammatory 
cytokines and reactive oxygen and nitrogen species) (Streit, 2004), resulting in the manifestation of 
several characteristic AD-pathologies such as neurodegeneration, neuroinflammation, neurotoxicity 
and oxidative damage (amyloid cascade-neuroinflammation hypothesis). On one side, 
neuroinflammation could be a beneficial event, inducing an immune response to start the phagocytosis 
of amyloid species in an attempt to limit the development of the disease. On the other side, prevailing 
evidence suggests that neuroinflammation is a driving force in the acceleration of AD development as 
it triggers the production of proinflammatory chemokines, cytokines, and neurotoxins by the activated 
microglia and astrocytes in the brain. It should also be recognised that microglia exist in a spectrum of 
functional phenotypes that may reflect helpful (e.g. A clearance) or harmful (e.g. over-production of 
pro-inflammatory cytokines and free radicals) roles. Recently, approaches to selectively upregulate the 
helpful functions of microglia have received increased attention (Perry et al., 2010, McGeer and 
McGeer, 2015) 
 
1.2 Treatment of Alzheimer’s disease 
Given the looming burden of AD, pharmacological regimens that could delay or even prevent the onset 
of AD would offer tremendous public health benefits. Based on the complex pathology of AD, a 
preventative, multimodal drug approach targeting a combination of pathological AD events early in 
disease development appears ideal. Unfortunately, current AD treatments only provide limited relief for 
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cognitive and functional decline in the early stages of the disease and are ineffective against disease 
progression (Zandi and Breitner, 2001, Benito et al., 2007, Marchalant et al., 2008, Karl et al., 2012). 
Furthermore, these treatment options cause a range of adverse side effects (e.g. nausea, vomiting, 
abdominal pain, headache, depression, and dizziness) (Benito et al., 2007, Micale et al., 2007, 
Marchalant et al., 2008). Therefore, it is necessary to explore new therapeutic avenues. Importantly, 
cannabinoids show anti-inflammatory, neuroprotective and anti-oxidant properties and have 
immunosuppressive effects. More recently, cannabinoids have also been found to possess properties 
that may reduce Aβ and tau pathology. Thus, cannabinoid-related intervention strategies may have 
therapeutic properties in AD. The phytocannabinoid cannabidiol (CBD) is of particular interest as it 
lacks the psychoactive and cognition-impairing properties of other cannabinoids. What is currently 
known about CBD’s pharmacological properties and its potential role in AD therapy will be outlined in 
the following sections. 
 
2. Cannabidiol (CBD) 
The phytocannabinoid CBD was first isolated from cannabis sativa in 1940 (Adams, 1940) and its 
structure was elucidated in the 60’s (Mechoulam and Gaoni, 1965). CBD has very low toxicity. The 
LD50 after intravenous administration to the rhesus monkey is 212 mg/kg whereas the oral LD50 could 
not be established, probably due to the fact that CBD is barely absorbed systemically after oral 
administration (i.e. oral bioavailability ranges between 13% and 19%) (Mechoulam et al., 2002). If 
injected, CBD is rapidly distributed and easily passes the blood–brain barrier due to its lipophilicity, 
which in turn provides CBD a prolonged elimination (Grotenhermen 2003). A high volume of 
distribution (~32 l/kg) has been estimated, with rapid distribution not only in the brain but also adipose 
tissue and other organs (Devinsky et al., 2014). Preferential distribution to fat raises the possibility of 
accumulation of CBD depots in chronic administration schemes, especially in patients with high 
adiposity. The metabolism of CBD shows biotransformation routes typically observed for 
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phytocannabinoids [but species differences must be considered when assessing preclinical research 
data, see (Bergamaschi et al., 2011)]. CBD undergoes multiple hydroxylations, oxidations to carboxylic 
acids, β-oxidation, conjugation, and epoxidation (Harvey et al., 1991). Eventually, CBD is 
preferentially excreted in urine, both in the free state and as its glucuronide, with a half-life of 9 h 
[reviewed in (Iuvone et al., 2009)].  
CBD pharmacological properties range from anti-convulsive, anti-anxiety, and anti-psychotic (Zuardi 
et al., 1991, Zuardi et al., 1995, Leweke et al., 2000, Schneider et al., 2002) to anti-nausea, anti-
inflammatory, and anti-rheumatoid arthritic [outlined more comprehensively in (Pertwee, 2008, Russo, 
2011)]. Importantly, CBD is a multi-target drug that can interact with many signaling systems 
including the endocannabinoid system (outlined in more detail in section 2.2).  
 
2.1 Brief introduction to the endocannabinoid system 
The endocannabinoid system (ECS) is an intercellular signalling system comprised of G-protein 
coupled cannabinoid receptors 1 (CB1) and 2 (CB2) as well as more recently discovered receptors (e.g. 
N-arachidonyl glycine receptor or G-protein coupled receptor 18: GPR18); endogenous ligands, the 
best characterised ones being the arachidonic acid derivatives Ν-arachidonoylethanolamine (also called 
anandamide: AEA) and 2-arachidonoylglycerol (2-AG) and their homologues; and metabolic enzymes 
(for overview see Table 1). The enzymes responsible for the biosynthesis of AEA require complete 
characterisation but a N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) has been 
implicated in the process as has diacylglycerol lipase- (DAGL-) for 2-AG. Metabolism of 
anandamide and 2-AG require fatty amide acid hydrolase (FAAH) and monoacylglycerol lipase 
(MAGL) respectively (Piomelli, 2003, Howlett et al., 2011). The ECS is involved in a variety of 
physiological processes including appetite, pain sensation, mood, and cognition. There are two main 
groups of cannabinoids that interact with the receptors of the ECS, namely the endogenous ligands (i.e. 
2-AG and AEA) and exogenous cannabinoids. Exogenous cannabinoids include various 
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phytocannabinoids derived from the marijuana plant, Cannabis sativa, including Δ9-
tetrahydrocannabinol (THC), the main psychoactive and cognition-impairing component, CBD, as well 
as synthetic cannabinoids (i.e. cannabimimetics such as CP 55,940 and WIN 55,212-2) (Tanasescu and 
Constantinescu, 2010) (for overview see Table 1). 
CB1 receptors are highly expressed throughout the brain by many different classes of neurons and also 
at lower levels by glial cells and many peripheral cell types (Pertwee, 2008). These receptors are found 
in abundance in the basal ganglia, cerebellum, and more importantly the hippocampus, 
parahippocampal and entorhinal cortices, suggesting an involvement of CB1 in learning and memory. 
CB1 has also been implicated in cannabinoid-mediated modulation of immune functions (Cabral et al., 
2008). CB2 receptors are predominantly found on a variety of immune cells including B lymphocytes, 
natural killer cells, monocytes/macrophages, and T cells suggesting a role in immunomodulation. 
Importantly, CB2 is also densely expressed on activated microglia cells, which suggests a possible role 
in mediating neuroinflammatory responses in the CNS. Stimulation of CB2 receptors in microglia not 
only drives the proliferation and migration of microglia, but can also block their differentiation into a 
neurotoxic phenotype (Stella, 2010). 
Radioligand binding studies into the developmental pattern (neonatally until 32 months of age) of 
cannabinoid receptors in the rat brain using the full CB1 and CB2 agonist CP 55,904 revealed that 
cannabinoid receptor binding capacity increases progressively from birth to postnatal day (PND) 60 in 
whole brain preparations whereas no further changes in binding are detected in adulthood and 
throughout the normal aging process (Belue et al., 1995). Interestingly, and in line with emerging 
evidence suggesting that Aβ depositions in AD brain are the result of impaired clearance, is the fact 
that activation of CB1/CB2 by 2-AG as well as the suppression of the endocannabinoid-degrading 
enzyme MGL (but not FAAH or ABHD6) elevates Aβ clearance across the blood-brain barrier 
(Bachmeier et al., 2013). 
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2.2 CBD pharmacology 
CBD effects on the endocannabiniod system  
The pharmacokinetic plasma pattern of CBD resembles that of THC, as does its metabolic pattern 
(Grotenhermen, 2003). CBD has been found to have very low displacement activities at CB1 and CB2 
receptors compared to other cannabinoids such as THC and WIN 55,212-2 (Thomas et al., 1998). 
Another study in the same year confirmed that CBD has a very low affinity (micromolar range) for CB1 
as well as CB2 receptors. More importantly, that work suggested that CBD develops antagonistic-like 
properties against the synthetic cannabinoid, CP 55,940, which is a full and highly potent agonist of 
CB1 and CB2 receptors, and that CBD has no agonistic activity of cannabinoid receptors even at high 
concentrations (Petitet et al., 1998). These findings were in line with earlier reports showing that CBD 
can reverse behavioural effects induced by THC (Karniol et al., 1974, Zuardi et al., 1981) although the 
study by Petitet and coworkers found no blockade of CP 55,940-induced hypothermia in mice by CBD. 
Interestingly, another study found that CBD antagonises (or inversely agonises) not only CP 55,940 but 
also WIN 55,212-2. But because CBD produced this antagonism at concentrations well below those at 
which it binds to cannabinoid receptors, the authors concluded that CBD acts at prejunctional sites that 
are unlikely to be CB1 or CB2 receptors (Pertwee et al., 2002). In a follow-up study, CBD displayed 
inverse agonism at human CB2 receptors and was a high potency antagonist (non-competitive) of 
cannabinoid receptor agonists in mouse brains as well as in membranes from CHO cells transfected 
with human CB2 (Thomas et al., 2007). CBD induced inverse agonism at CB2 receptors at 
concentrations well below those at which it displaces CP 55,940. This characteristic of CBD may 
contribute to its anti-inflammatory properties, as there is evidence that CB2 inverse agonism can inhibit 
immune cell migration (Lunn et al., 2006). In line with this, CBD is a potent inhibitor of evoked 
migration both of murine microglial cells and macrophages and of human neutrophils [reviewed in 
(Pertwee, 2008)]. In addition, CBD appears to be an antagonist on GPR55 (Ryberg et al., 2007) and on 
GPR18 (McHugh et al., 2010) receptors and activates the putative abnormal CBD receptor (Pertwee, 
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2005, 2008). Bisogno and coworkers discovered that CBD also interacts with vanilloid receptor type 1 
(VR1), the receptor for capsaicin (Bisogno et al., 2001), as it stimulated VR1 with a maximal effect 
similar in efficacy to that of capsaicin suggesting that VR1 may mediate some of the pharmacological 
effects of CBD (VR1) (Bisogno et al., 2001). Finally, there is limited evidence that suggests CBD 
might also activate VR2 (Izzo et al., 2009). 
CBD also impacts brain endocannabinoid levels directly. An initial study reported interactions between 
CBD and proteins that inactivate AEA (Bisogno et al., 2001). CBD inhibited AEA uptake and, to a 
lesser extent, AEA hydrolysis. These findings suggested that increased levels of endogenous AEA due 
to CBD-induced inhibition of AEA uptake and degradation (Watanabe et al., 1996) might mediate 
some of the pharmacological effects of CBD. Supporting this idea is another study, which reported that 
CBD blunts the expression and the activity of FAAH, the enzyme required for the degradation of both 
AEA and 2-AG (de Filippis et al., 2008, Leweke et al., 2012). 
CBD effects on other neurotransmitter systems and brain processes 
The role of CBD in brain circuits other than the endocannabiniod system has also been evaluated. In 
1998, CBD was found to protect against neurotoxicity mediated by glutamate receptors, i.e. N-methyl-
D-aspartate (NMDA) receptors, 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid (AMPA) 
receptors, and kainate receptors (Hampson et al., 1998). CBD has also been reported to exhibit a 
modest agonistic affinity of human 5-HT1a receptors (Russo et al., 2005), where it inhibits 5-HT re-
uptake, and reduces overall 5-HT neurotransmission [reviewed in (Pertwee, 2004)]. In line with the 
earlier statement that CBD has species-dependent properties, CBD discriminated between human and 
rat orthologues of the 5-HT1A receptor (Russo et al., 2005). Furthermore, CBD enhanced adenosine 
receptor A2A signalling via inhibition of cellular update of an adenosine transporter (Carrier et al., 
2006). This effect may be at least partially responsible for CBDs ability to decrease inflammation and 
to be neuroprotective. Although not relevant for the in vivo effects (as CBD doses required were not 
biologically relevant), CBD was reported to possess allosteric modulator properties for μ- and δ-opioid 
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receptors at very high concentrations (i.e. dissociation rate induced by naloxone and naltrindole at 
receptors was accelerated by 100 µm CBD) (Kathmann et al., 2006). This is an interesting finding 
considering that δ-opioid receptors can form a complex with β- and γ-secretases thereby promoting the 
processing of APP to Aβ (Teng et al., 2010). Finally, there is also some experimental evidence to 
support CBD activity in other pathways such as the dopamine and GABA neurotransmitter systems 
[reviewed in (Pertwee, 2004)]. 
It has also been shown that CBD can increase adult hippocampal neurogenesis (Wolf et al., 2010). 
Interestingly, this effect is absent in CB1 knockout mice suggesting that the effect of CBD on 
neurogenesis is mediated by an indirect activation of CB1 receptors, possibly via inhibition of AEA 
metabolism/uptake (as discussed earlier). Supporting this finding is a recent in vitro study showing that 
CBD increases proliferation of hippocampal progenitor cells in culture, which can be prevented by 
antagonists for both CB1 and CB2 receptors or overexpression of FAAH (Campos et al., 2011). Further, 
AD-specific pharmacological actions of CBD have been reported. These will be outlined in more detail 
in the following sections (in particular, sections 3.1 and 3.2) where the therapeutic properties of CBD 
in preclinical models for the disease are discussed (for full overview of pharmacological actions of 
CBD see Table 2). 
 
3. CBD: A new treatment option for Alzheimer’s disease – a preclinical perspective 
As discussed in section 2.2, the molecular mechanisms in which CBD exerts its various effects are still 
under debate with evidence suggesting that its actions are not confined to the receptors of the 
endocannabinoid system. Importantly for this review, a number of studies provide evidence that CBD 
exerts various properties including neuroprotection, anti-inflammatory and anti-oxidant effects, and is 
able to modulate the function of the immune system [as reviewed in (Campbell and Gowran, 2007, 
Pertwee, 2008, Izzo et al., 2009, Scuderi et al., 2009, Booz, 2011)]. This evidence will be outlined in 
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the following sections in the context of in vitro (section 3.1) and in vivo models (section 3.2) relevant to 
AD. 
 
3.1 Effects of CBD on in vitro Alzheimer’s disease models 
Tau pathology 
CBD was reported to suppress the hyperphosphorylation of tau protein in Aβ-stimulated PC12 neuronal 
cells in a dose-dependent manner. The CBD-induced suppression was associated with a reduction of 
phosphorylated glycogen synthase kinase 3-β (p-GSK3-β), the active form of GSK3-β, a 
multifunctional phosphorylating serine/threonine kinase (Esposito et al., 2006a). Importantly, active p-
GSK3-β is also known as tau protein kinase and is responsible for tau protein hyperphosphorylation 
and NFT formation in brains of patients with AD (Sperber et al., 1995). GSK3-β activation also 
induces Aβ overproduction because of its impact on APP processing (Phiel et al., 2003). Furthermore, 
Aβ peptide induces GSK3-β phosphorylation in hippocampal and cortical neurons thereby disrupting 
the Wnt signalling function (Garrido et al., 2002). Aβ–induced Wnt pathway disruptions are pivotal 
events in the neuronal apoptosis characteristic of AD, involving p-GSK3-β upregulation and β-catenin 
degradation (De Ferrari and Inestrosa, 2000). In line with this, β-catenin levels are decreased in brains 
of AD patients (Satoh and Kuroda, 2000). These data suggest that CBD inhibits tau 
hyperphosporylation by disrupting phosphorylation of GSK3-β and thereby rescues at least some 
aspects of the Wnt signalling pathway. Importantly, pharmacological interventions that rescue Wnt 
activity have been proposed as novel therapeutics for AD treatment in the past (Esposito et al., 2006a). 
Amyloid β pathology 
Direct modulatory effects of CBD on APP processing have only recently been evaluated in in vitro 
studies. Transfected human neuroblastoma SHSY5YAPP+ cells exhibited significantly elevated full-
length APP expression compared to control neuronal cells (Scuderi et al., 2014). CBD counteracted this 
elevation in a dose-dependent manner by inducing ubiquitination of APP without having any effect on 
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control cells. The CBD effect on SHSY5YAPP+ cells was paralleled by a progressive reduction of Aβ 
peptide expression in cell lysates and consequentially less apoptopic events (i.e. number of apoptopic 
cell bodies and % neuron survival) in these cells (Scuderi et al., 2014). Importantly, the peroxisome 
proliferator-activated receptor-γ (PPARγ) antagonist GW9662 blocked these effects of CBD whereas 
the involvement of α-, β- and γ-secretases were ruled out. PPARs are ligand-activated transcription 
factors that belong to the nuclear hormone receptor superfamily and include three isoforms (i.e. α, β/δ, 
and γ). PPARs have been linked to inflammation, cell proliferation, and differentiation. Importantly, 
PPARγ receptors are expressed at low levels under physiological conditions but rise in response to 
some pathological situations including AD (Kitamura et al., 1999). In line with this, PPARγ activation 
has been found to reduce APP expression (d'Abramo et al., 2005) and dramatically enhance clearance 
of Aβ in vitro (Camacho et al., 2004). Thus, CBD may exert a beneficial effect on the amyloidogenic 
pathway through a mechanism involving PPARγ. This presents a novel promising avenue to counteract 
the progression of AD and would be in line with suggestions that regulating PPARγ activity may be 
therapeutically effective for AD pathophysiology. Related to the impact CBD has on the amyloidogenic 
pathway, other synthetic cannabinoids (i.e. the CB2 agonist JWH-015) have been found to increase the 
phagocytosis of Aβ by mouse microglial cells (Ehrhart et al., 2005) and promote the removal of Aβ 
from human frozen tissue sections at low doses (Tolon et al., 2009). Importantly, CB2 expression is 
upregulated in glial cells under chronic neuroinflammatory conditions such as AD. 
Aβ-induced toxicity  
CBD dose-dependently alleviated various other effects of Aβ-induced toxicity in a cultured rat 
pheocromocytoma PC12 cell model (Iuvone et al., 2004). CBD administration prior to Aβ treatment 
improved cell survival, reduced lipid peroxidation and production of reactive oxygen species (ROS). 
ROS have been found to play a role in Aβ-induced cell damage and death (Brera et al., 2000) The 
phytocannabinoid also increased caspase 3 protein levels (used as a hallmark of apoptosis), DNA 
fragmentation and intracellular calcium levels, which were elevated in Aβ-treated cells without CBD 
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treatment. Importantly, caspases are essential mediators of many of the pathways involved in executing 
the apoptopic programme following Aβ accumulation (Nicholson and Thornberry, 1997). Furthermore, 
Aβ-induced DNA fragmentation, a hallmark of apoptosis, has previously been found in AD models 
(Gschwind and Huber, 1995), and a rise in calcium levels has been suggested to be responsible for at 
least some of the toxic effects of Aβ (Mattson, 2002). Finally, an Aβ-induced decrease in the pro-
caspase 3/total caspase 3 ratio was counteracted by CBD, suggesting that CBD could exert a protective 
role at the execution phase of apoptosis, as activation of procaspase 3 to caspase 3 normally serves as 
the convergence point of different apoptotic signalling pathways (Iuvone et al 2004). The effects of 
CBD appeared to be independent of CB1 receptors, as SR141716A treatment (a CB1 receptor 
antagonist) did not modulate the CBD properties observed. The authors concluded that CBD exerts a 
combination of neuroprotective, anti-oxidant, and anti-apoptotic effects against Aβ-induced toxicity.  
In line with the above findings, stimulation of PC12 cells with Aβ caused a significant increase in 
nitrite production and inducible nitric oxide synthase (iNOS) protein expression. iNOS and its 
enzymatic product nitric oxide (NO) are among the most important neurotoxic effectors in AD. NO is 
predominantly released by activated glial cells and may disrupt neurons thereby sustaining the pro-
inflammatory conditions typical for AD (Cardenas et al., 2005). CBD inhibited these consequences of 
Aβ toxicity dose-dependently. This neuroprotective effect of CBD was mediated by suppressing the 
Aβ-induced increase in phosphorylation of p38 mitogen-associated protein kinase (p38 MAP kinase) 
and activation of nuclear factor-ĸB activation (NF-ĸB) (Esposito et al., 2006b). The transcription factor 
NF-ĸB is stimulated by stress-responsive protein kinases (e.g. p38 MAP kinase) and regulates the 
expression of genes involved in cell differentiation, proliferation and apoptosis as well as oxidative and 
inflammatory responses. Furthermore, NF-ĸB activation is required to induce iNOS protein 
transcription in post-mortem AD brains (Haas et al., 2002). 
A more recent study was not able to confirm the neuroprotective effects of CBD: CBD protected rat 
PC12 peripheral neuronal cells and human SH-SY5Y cells against oxidative stress and lipid 
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peroxidation induced by tert-butyl hydroperoxide but failed against Aβ1-40 fibril and aggregate-evoked 
neurotoxicity (Harvey et al., 2012). This unexpected finding was probably due to the fact that the 
previous studies incubated cells with non-fibrillar Aβ, whereas Harvey et al. utilised Aβ in its 
preformed (fibrillar) state when incubating the neuronal cell lines. Thus the neuroprotective efficacy of 
CBD appears dependent on Aβ fibril formation occurring during cell exposure, which implies either a 
direct influence on fibril formation or interference with Aβ fibril uptake or processing. CBD was 
neuroprotective against oxidative stress generated from tert-butyl hydroperoxide but not from Aβ 
exposure as there are differences in the neurotoxicity profile caused by these two stressors. It is likely 
that Aβ activates additional pathways in evoking cell death that are not surmountable via antioxidant 
capacity alone whereas tert-butyl hydroperoxide will directly attack membrane lipids (Harvey et al., 
2012). Interestingly, AEA effectively protected neuronal cells against Aβ fibril and aggregate-evoked 
neurotoxicity via a pathway unrelated to CB1 or CB2 receptor activation, although both neuronal cell 
lines expressed CB1 receptors (low expression of CB2 only) (Harvey et al., 2012). 
The same team went on to analyse the potential inhibition of native Aβ fibrils and oligomer formation 
by CBD (and other cannabinoids, e.g. THC, JWH-015 and 2-AG). Human neuroblastoma SHSY5Y 
cells were exposed to Aβ42 directly and cell viability was measured in the presence of CBD. SHSY5Y 
cells were also exposed to microglia-conditioned media (BV-2 cells) activated with lipopolysaccharide 
(LPS), albumin or Aβ42, after which TNF-α and nitrite production were evaluated following CBD 
treatment (Janefjord et al., 2014). Aβ42 evoked a concentration-dependent loss of cell viability in 
SHSY5Y cells but negligible TNF-α and nitrite production in BV-2 cells compared to LPS or albumin. 
CBD protected against Aβ–induced cell viability loss directly as well as against LPS-activated BV-2 
conditioned media viability loss. CBD also altered the morphology of Aβ fibrils and aggregates to 
some extent (but to a lesser degree than other cannabinoids). However, there was no clear correlation 
between changed morphology and neuroprotective actions. In line with the previous study outlining the 
role of endocannabinoids in Aβ–relevant neuroprotection (Harvey et al., 2012), of all the other 
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cannabinoids used, only the endocannabinoid 2-AG was found to provide significant and direct 
neuroprotection against Aβ42 (Janefjord et al., 2014). The authors raised another interesting point: there 
was a trend for cell viability levels to be improved in the CBD control group (i.e. without Aβ 
pretreatment). This may point towards a cellular proliferative or mitochondrial stabilising effect of 
CBD that could potentially offset the loss of viability induced by Aβ42.  
Microglial function 
A consistent pathology of AD is glial activation. Microglia are the resident macrophages of the brain 
and play a major role in the active immune defense of the CNS against pathological events. When 
membrane receptors of microglia are activated [e.g. by adenosine triphosphase (ATP), which is 
released by dying cells], these glial cells migrate towards the site of injury and release e.g. pro-
inflammatory cytokines and NO. In AD, microglia overstimulation may be responsible for the 
inflammatory conditions typically found in patient brains and may result in neurodegeneration. Thus, 
pharmacological manipulation of microglia activity may have therapeutic potential for 
neurodegenerative diseases in general and for AD in particular. However, microglia can have helpful 
and harmful phenotpyes. Thus, it is very likely that a balanced immune-modulation is required for AD 
therapy, as immune activation of microglia can clear plaques whereas chronic neuroinflammation can 
cause neuronal death/dysfunction (Krause and Muller, 2010). 
Walter and colleagues (2003) discovered that microglia express both CB1 and CB2 receptors. 
Furthermore, stimulation of microglia with ATP in vitro increased the production of 2-AG and 
triggered glial cell migration (Walter et al., 2003). Importantly, CBD prevented the 2-AG-induced 
migration of microglial cells possibly via antagonism at CB2 and ‘abnormal CBD’ receptors [for the 
latter see (Jarai et al., 1999)]. In line with this, another study found that several synthetic cannabinoids 
blocked Aβ-induced activation of cultured microglia, which was assessed by microglial cell activity, 
morphology, and TNF-α release (Ramirez et al., 2005). This effect was evident for HU-210 but also for 
cannabinoids with CB2 selectivity (i.e. JWH-133) and no anti-oxidant properties (i.e. WIN 55,212-2). 
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Interestingly, JWH-133 was as effective as the mixed CB1/CB2 agonist WIN 55,212-2 in the inhibition 
of microglia activation (Ramirez et al., 2005). A more recent study confirmed and expanded on these 
findings, as not only WIN 55,212-2 and JWH-133 but also CBD dose-dependently decreased the ATP-
induced increase in intracellular calcium in cultured N13 microglial cells and in rat primary microglia. 
The properties of CBD in the N13 cell model were independent of its actions on CB1 and CB2 receptors 
whereas those properties could be blocked by CB2 antagonism in the primary microglia model (Martin-
Moreno et al., 2011). The research team also investigated a potential involvement of adenosine 
receptors and found that an agonist of the adenosine A2A receptor (i.e. CGS-21680) mimicked the 
actions of CBD. More importantly, an A2A antagonist (i.e. ZM241,385) suppressed the effects of CBD 
in both the N13 and the primary microglial cell models (Martin-Moreno et al., 2011). Finally, CBD 
promoted primary microglial migration, a phenomenon which could be stopped by CB1 and CB2 
receptor antagonism (i.e. SR141716 and SR144528 respectively). 
Acetylcholine 
It is important to realise that Aβ not only induces neurodegeneration but also has downstream effects 
including the severe disruption of several neurotransmitter systems. For example, cholinergic neurons 
are lost in brain areas relevant for memory processing (i.e. amygdala, hippocampus and frontal cortex) 
and this deterioration is accompanied by a decrease in acetylcholine (ACh), which plays a crucial role 
in cortical development and activity and the modulation of cognition, learning and memory (Schliebs 
and Arendt, 2011). So far, no research has been carried out to determine the effects of CBD on the 
cholinergic system and the ACh-releated changes in AD. However, it is interesting to note that the 
phytocannabinoid THC was found to completely inhibit the enzyme actylcholinesterase and its 
aggregating effect on Aβ in vitro (and does so more effectively than currently approved AD 
interventions such as donepezil and tacrine) (Eubanks et al., 2006).  
Glutamate 
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Aβ can also cause long-term disruptions to glutamatergic neurotransmission (Schliebs and Arendt, 
2011). Under normal physiological conditions, glutamate activates NMDA receptors, allowing calcium 
ions (Ca2+) to flow into the post-synaptic neuron. This triggers a signalling cascade that produces 
synaptic plasticity including long-term potentiation (LTP), thereby facilitating higher order processes 
such as learning and memory (Parsons et al., 2013). In AD, NMDA receptors are overstimulated by the 
presence of excess glutamate, leading to sustained Ca2+ influx. This prolonged Ca2+ overload increases 
the production of NO, inhibiting mitochondrial activity and depleting intracellular ATP levels 
(Takeuchi, 2010). The loss of energy results in impaired dendritic and axonal transport, and neuronal 
function, generating an excitotoxic state and eventually neurodegeneration. In this context, it is 
important to remember that CBD has been shown to reduce glutamate-, NMDA-, AMPA-, and kainate-
induced toxicity in rat cortical neurones (Hampson et al., 1998). However, the direct effect of CBD on 
the glutamatergic system in an AD-relevant context has not been investigated yet. 
 
3.2 Effects of CBD on in vivo Alzheimer’s disease models 
There is a body of literature available evaluating the therapeutic-like effects of THC and synthetic 
cannabinoids on AD-relevant behaviours and brain pathology [e.g. (Ramirez et al., 2005, Aso et al., 
2013)]. The available in vivo evidence for the therapeutic properties of CBD in AD is much sparser. 
Pure CBD was found to be inactive in cognitive domains of healthy rhesus monkeys and mice [e.g. 
(Lichtman et al., 1995, Winsauer et al., 1999, Long et al., 2010)] although there is also limited evidence 
that CBD i) facilitates extinction of a contextual fear memory in rats (Bitencourt et al., 2008) and ii) 
blocks reconsolidation of aversive memories in rodents (Stern et al., 2012). Furthermore, work utilising 
cannabis plant extract either high in CBD or THC revealed that acute treatment with CBD-rich extracts 
did not impact the working memory of healthy rats in a delayed-matching-to-place task in the water 
maze whereas THC-rich extracts impaired cognitive performance (Fadda et al., 2004). Interestingly, 
CBD-rich extracts given concomitantly with THC-rich extracts did not block the memory-impairing 
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(and catalepsy-inducing) effects of THC. It has been suggested that a >10-fold higher dose of CBD 
over THC is necessary to effectively antagonise THC-mediated behavioural deficits [(Fadda et al., 
2004) – see also (Zuardi and Karniol, 1983)] (for further details on CBD-THC combination 
treatments/effects see section 5.1).  
Mouse models developing AD-relevant phenotypes 
The following in vivo findings were not obtained in AD models but may be relevant to some of the 
AD-related pathological and behavioural characteristics. In a mouse model for chronic liver disease, 
CBD had therapeutic effects on hepatic encephalopathy [i.e normalising increased TNF-α receptor 1 
gene and decreased brain-derived neurotrophic factor (BDNF) expression] and improved cognitive 
functioning, which is impaired in mouse models for chronic liver disease (Magen et al., 2009). The 
majority of CBD effects were blocked by pharmacological antagonism at A2A receptors. A follow-up 
study by the same research team also discovered an involvement of 5-HT1A receptor activation in the 
beneficial properties of CBD treatment in this model (Magen et al., 2010). However, CBD-induced 
BDNF expression changes were not mediated by either receptor suggesting the involvement of yet to 
be discovered pathways. 
Iron content in brain appears positively correlated with poorer cognitive performance of AD patients 
(Ding et al., 2009). Furthermore, iron-induced memory impairments are associated with increased 
oxidative stress markers in the brain (de Lima et al., 2005). Thus, iron-induced cognitive deficits might 
be linked to oxidative damage and the anti-oxidant properties of CBD might be beneficial in this 
context. Indeed, high dose acute CBD as well as subchronic CBD treatment recovered the object 
recognition memory performance of iron-treated rats without affecting cognition of control rats 
(Fagherazzi et al., 2011).  
Pharmacological rodent models for Alzheimer’s disease 
Manipulations to the endocannabinoid system: AD-relevant experimental strategies were implemented 
for the first time when Mazzola and coworkers found that the amnesic effects of Aβ25-35 and Aβ42 
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(measured in mice using the step-through passive avoidance test) could be blocked by co-treatment 
with the CB1 antagonist SR141716A (Mazzola et al., 2003). Another study using pharmacological 
rodent models for AD evaluated changes to the endocannabiniod system after rats had been exposed to 
cortical Aβ42 administration. Aβ42 enhanced hippocampal 2-AG (but not AEA) levels concomitant with 
the appearance of markers of neuronal damage, increased CB2 (but not CB1) protein expression, and 
induced cognitive deficits in the passive avoidance task. Inhibition of endocannabinoid cellular 
reuptake reversed hippocampal damage and loss of memory retention (but only when given early after 
Aβ42 administration) (van der Stelt et al., 2006). These data suggested for the first time that early 
modifications to the endocannabinoid system might protect against Aβ neurotoxicity and its 
consequences. Indeed, detrimental effects of bilateral injection of Aβ40 fibrils into the hippocampal 
CA1 area of rats on spatial memory and neuroinflammation (e.g. microglia and astrocyte activation, IL-
1β expression and Aβ clearance) were reversed by subchronic treatment with MDA7, a selective CB2 
receptor agonist. Furthermore, Aβ40 injections were accompanied by increased hippocampal CB2 
expression (Wu et al., 2013). 
CBD treatment: Most relevant to this review are studies testing CBD in pharmacological models for 
AD. When mice were inoculated with Aβ42 in the hippocampus and co-treated with CBD (i.p. route), 
CBD dose-dependently suppressed Aβ-induced increases in glial fibrillary acidic protein (GFAP) 
mRNA and protein expression (i.e. a marker of activated astrocytes) and reduced Aβ-induced iNOS 
and IL-1β protein expression, and the related NO and IL-1β release (Esposito et al., 2007). IL-1β is 
involved in events related to neurodegeneration including synthesis and processing of APP and 
astrocyte activation, which is followed by iNOS over-expression and excessive production of NO. 
Thus, CBD was effective in counteracting aspects of the neuroinflammatory response to Aβ challenge 
and a CB2-related mechanism was put forward by the authors (Esposito et al., 2007). Interestingly, CB2 
overexpression has been detected in an Aβ-induced rat model of reactive gliosis (van der Stelt et al., 
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2006), and CB2 affects reactive gliosis at neuroinflammatory sites, thereby playing a role in the 
progression of brain damage (Walter and Stella, 2004). 
Confirming the cognition-rescuing and anti-inflammatory effects of CBD reported by Esposito and co-
workers is another study that determined the effects of chronic CBD treatment on these domains in 
mice injected i.v.c. with fibrillar Aβ. CBD treatment reversed the compromising effects of Aβ on 
Morris water maze learning (no data were available for the memory consolidation and retention of 
these mice). CBD did not alter the Aβ–induced increase in TNF-α mRNA expression but decreased 
levels of IL-6 (Martin-Moreno et al., 2011). 
Transgenic mouse models for Alzheimer’s disease 
The endocannabinoid system in AD transgenic mice: A limited number of studies paid close attention 
to the expression profile of the cannabinoid receptors CB1 and CB2 in the context of AD. CB1 
immunoreactivity was reduced in hippocampal regions (i.e. CA1 and CA2/3) of APPxPS1 mice, an 
established transgenic mouse model for familial AD (Kalifa et al., 2011). This CB1 phenotype was 
associated with astroglial proliferation and elevated expression of the iNOS and TNF-α suggesting that 
lower CB1 expression levels in AD transgenic mice may diminish anti-inflammatory processes thereby 
exacerbating AD-associated pathology. Another study found no changes to CB2 protein expression in 
APP transgenic mice (Martin-Moreno et al., 2012). Finally, a triple AD transgenic mouse model (i.e 
harboring PS1M146V, APPSwe, and TauP301L transgenes), exhibited increased CB1 expression in prefrontal 
cortex, dorsal hippocampus, and basolateral amygdala complex, whereas expression levels were lower 
compared to control mice in the ventral hippocampus from 6 months of age onwards (Bedse et al., 
2014). 
Expanding on these earlier findings, APP23 transgenic mice were crossed with CB1 knockout mice to 
study the impact of CB1 deficiency on AD pathology (Stumm et al., 2013). Most double mutant mice 
died before the onset of AD pathology but surviving mice exhibited reduced levels of APP and its 
fragments which were accompanied by a reduced plaque load and less inflammation. These findings 
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point to a regulatory role of CB1 on APP processing. Compared to APP23 transgenic and CB1 knockout 
mice, double mutant APP23/CB1 mice showed even more impaired learning and memory deficits in the 
Morris water maze. 
Manipulations to the endocannabinoid system: Moving on from these expression studies using AD 
transgenic mice, a small number of research teams have evaluated the effects of cannabinoids other 
than CBD on AD-relevant behaviours and brain pathology of established transgenic mouse models for 
the disease. Martin-Moreno and co-workers studied the effects of prolonged oral administration of 
WIN 55,212-2 or JWH-133 on cognition and inflammation in APP transgenic mice (i.e. for 4 months 
starting at 7 months, prior to plaque pathology and cognitive deficits). The CB2 agonist JWH-133 (but 
not WIN 55,212-2) prevented the development of object recognition memory impairments (Martin-
Moreno et al., 2012). Furthermore, glucose uptake in the brain (as measured by 18F-fluoro-
deoxyglucose (18FDG) uptake using PET), which is reduced in AD patients and correlated with 
cognitive deficits, was reduced in AD transgenic mice. Finally, JWH-133 intervention fully reversed 
this phenotype. Looking at neuroinflammation in this model system, JWH-133 normalised the density 
of ionised calcium binding adaptor molecule 1 (Iba1)-positive microglia (increased in AD transgenic 
mice) and both JWH-133 and WIN 55,212-2 reduced the enhancement of COX-2 protein levels and 
TNF-α mRNA expression (both increased in AD patients and AD transgenic mouse models). 
Futhermore, the synthetic cannabinoids were able to reduce the enhanced levels of Aβ40 and of the 
more amyloidogenic Aβ42 in APP mice, probably by enhancement of Aβ clearance through blood-brain 
or CSF-barrier (Martin-Moreno et al., 2012). Finally, WIN 55,212-2 (but not JWH-133) prevented 
reductions to p-GSK3-β in AD transgenic mice. 
A recent study confirmed most of these findings when treating APPxPS1 mice with JWH-133 at the 
pre-symptomatic stage (Aso et al., 2013). JWH-133: i) improved cognitive performance in the novel 
object recognition test and the active avoidance task; ii) decreased microglial reactivity and reduced 
expression of pro-inflammatory cytokines IL-1β, IL-6, TNFα, and IFNγ; iii) reduced the expression of 
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active p38 and stress-activated protein kinase/c-Jun NH(2)-terminal kinase (SAPK/JNK); iv) increased 
the expression of inactive GSK3β and lowered tau hyperphosphorylation; v) enhanced the expression 
of superoxide dismutase 1 (SOD1) and SOD2 around plaques; but, vi) did not alter Aβ production. 
Inconsistencies between these two studies (e.g. effects of JWH-133 on Aβ pathology and tau 
hyperphosphorylation-relevant pathways, i.e. GSK3-β) were attributed to methodological differences in 
regards to mouse model and treatment design chosen as well as specifics of biochemical analyses (Aso 
et al., 2013). In this context, it is important to note that other cannabinoids have been found to lack any 
therapeutic-like properties in AD transgenic mouse models [e.g. HU-210 in APP23/PS1 transgenic 
mice: (Chen et al., 2010)]. 
CBD+THC combination treatment: Two studies so far have explored the potential of CBD+THC 
combination compounds for AD therapy using AD transgenic mice (for further information on the 
potential and issues around combination treatments using THC and CBD see section 5.1). In a first 
experiment, Sativex® [mixture of a THC botanical extract (containing 67.1% THC, 0.3% CBD, 0.9% 
cannabigerol, 0.9% cannabichromene, and 1.9% other phytocannabinoids) and a CBD botanical extract 
(containing 64.8% CBD, 2.3% THC, 1.1% cannabigerol, 3.0% cannabichromene, and 1.5% other 
phytocannabinoids) in a 1:1 proportion] was administered i.p., daily for a month to parkin-null, human 
tau overexpressing (PK−/−/TauVLW) mice, which presents a model of complex frontotemporal dementia, 
parkinsonism, and lower motor neuron disease. Sativex® treatment resulted in less abnormal stress-
related behaviours (e.g. overgrooming and stereotypies; cognition was not assessed except spontaneous 
alternation version of the Y maze). Furthermore, the treatment reduced the metabolism of dopamine 
(but not the level of dopamine itself) as well as gliosis (e.g. Iba1 levels), neuroinflammation (e.g. 
GFAP levels), and iNOS levels in the cerebral cortex (Casarejos et al., 2013). Most relevant to AD is 
the finding that Sativex® decreased the concentration of phosphorylated tau and Aβ plaques in cortex 
and hippocampus and increased autophagy. The mechanism behind the effects of Sativex® has not 
been evaluated yet. 
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In a second study, botanical extracts high in THC (CBD content less than 0.5%) or high in CBD (THC 
content less than 2.5%) as well as a combination thereof (CBD plus THC) were used to treat APPxPS1 
transgenic mice at the early symptomatic phase (Aso et al., 2015). All three approaches preserved 
object recognition memory of AD transgenic mice but THC had detrimental effects on cognition in 
control mice. CBD+THC also reduced fear-associated learning impairments of APPxPS1 mice, 
decreased soluble Aβ42 (but not Aβ40) levels in the cortex and changed plaque composition (but total 
amyloid burden was unchanged). All cannabinoids reduced astrogliosis (decreased GFAP staining) but 
only CBD+THC reduced microgliosis (i.e. decreased Iba1 staining). CBD+THC was also most 
effective in reducing inflammation and modifying neuroinflammatory responses in APPxPS1 mice 
[mRNA expression levels; for details see (Aso et al., 2015)]. Interestingly, the redox protein 
thioredoxin 2 and the signaling protein Wnt16 were identified as significant substrates for the 
CBD+THC-induced effects in AD transgenic mice. Thioredoxin 2 is a key component of the 
mitochondrial antioxidant system that is responsible for the clearance of reactive intermediates and 
repairs proteins with oxidative damage. The Wnt gene family encodes secreted signaling proteins, 
which have been implicated in several developmental processes, including axon guidance during 
development and in response to traumatic injury. Moreover, activation of the Wnt signaling pathway 
prevents Aβ-induced neurotoxicity in vitro. 
Pure CBD treatment: Our team has expanded on the aforementioned studies evaluating the potential 
role of CB2 and CBD+THC combinations in AD therapy by focusing on CBD effects in AD transgenic 
mouse models. We have run two studies exposing AD transgenic mice and control literemates to 
chronic CBD (or vehicle) treatment, both to test for remedial as well as preventative properties of CBD 
for AD therapy. In the remedial arm of this study, we treated double transgenic APPswe/PS1∆E9 
(APPxPS1) chronically with CBD (daily i.p. injections) after the development of cognitive deficits and 
Aβ pathology. CBD rescued social recognition memory and reversed object recognition deficits of 
male APPxPS1 transgenic mice. These effects were specific for recognition memory as CBD had no 
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impact on fear-associated memory or anxiety behaviours (Cheng et al., 2014a). Impairments in object 
recognition have been linked to dysregulation of the glutamatergic system (Nilsson et al., 2007) and 
CBD has been found to augment the effects of a NMDA receptor antagonist in humans (Hallak et al., 
2011). Furthermore, CBD protects against glutamate neurotoxicity (Hampson et al 1998) and 
memantine, another NMDA receptor antagonist improved object recognition in another transgenic AD 
mouse model (Scholtzova et al., 2008). So CBD may improve recognition memory via the 
glutamatergic pathway. 
For the preventative research strategy, we treated APPxPS1 mice with CBD or vehicle using a daily 
voluntary oral administration scheme for 8 months beginning at 2.5 months of age when AD-like 
pathophysiology is still sparse. Long-term oral CBD treatment prevented the development of social 
recognition deficit in male APPxPS1 mice (Cheng et al., 2014b). The beneficial effect of CBD on 
social recognition memory was not associated with a direct effect on Aβ levels. Insoluble and soluble 
levels of Aβ40 and Aβ42 were no different between vehicle and CBD-treated APPxPS1 mice in cortex 
and hippocampus. Levels of oxidation were not significantly altered in APPxPS1 mice in comparison 
to their age-matched WT littermates, nor did we detect changes in the level of lipid oxidation in the 
cortex of CBD-treated animals, despite its known antioxidant properties. It is possible that brains were 
collected at an age (i.e. around 10 months of age), where nucleic acid oxidation differences between 
APPxPS1 and control mice are not evident anymore (normally observed at 3- 5 months of age). 
Although not significant, the data obtained based on the administration of one CBD dose only (i.e. 20 
mg/kg) suggested that CBD might have a beneficial effect on cytokine levels, in particular TNF-α, 
which would be in line with earlier findings discussed above [e.g. (Martin-Moreno et al., 2011)]. 
The study also revealed a complex relationship between CBD treatment, AD genotype, and brain levels 
of cholesterol and phytosterols. These findings will be followed up in future work. This is important as 
disturbances in brain cholesterol metabolism are associated with the major pathological features of AD 
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(including Aβ and tau pathology) and dietary phytosterols can either interfere with critical functional 
processes in AD or decrease amyloidogenic processing. 
 
4. The endocanabinoid system and cannabinoid therapy in Alzheimer’s disease patients  
To date there have been no clinical trials evaluating the therapeutic potential of CBD for AD. This is 
probably due to the limited number of preclinical research studies investigating the effects of CBD in 
AD thus far. However, two clinical trials testing CBD have been carried out, which have some 
relevance for AD. In 2009, an interventional study explored the value of CBD in treating cognitive 
dysfunction in schizophrenia (ClinicalTrials.gov identifier NCT00588731). The study was based on a 
six-week, randomized, placebo-controlled, fixed dose trial comparing CBD with placebo added to a 
stable dose of antipsychotic medications in patients diagnosed with schizophrenia. The second 
interventionial study (ClinicalTrials.gov identifier NCT01502046) started in 2011 and was a double 
blind, randomised, cross over, placebo-controlled phase 2 clinical trial to assess the neuroprotective 
properties of CBD, THC, and Sativex in Huntington’s disease patients. Unfortunately, it was not 
possible to obtain any information from the www.ClinicalTrials.gov website or from the lead 
investigators about the effects of CBD effects on cognition or neuroprotection in humans. Nevertheless, 
a few studies evaluated the role of the endocananbinoid system in AD patients and the effectiveness of 
cannabinoid treatment other than CBD in AD therapy and those findings will be outlined in the 
following. 
 
4.1 The endocannabinoid system in Alzheimer’s disease 
Westlake and colleagues carried out autoradiographic studies using [3H]CP 55,940 binding (i.e. 
synthetic CB1 and CB2 receptor agonist), in fresh frozen brain sections from normal aged humans, 
Alzheimer's disease patients, and patients who died with other forms of cortical pathology (Westlake et 
al., 1994). In AD brains, compared to normal brains, [3H]CP 55,940 binding was reduced in various 
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regions of the hippocampus and the caudate nucleus. Less significant reductions were detected in the 
substantia nigra and the globus pallidus. Other neocortical and basal ganglia structures were not 
different from control levels. Levels of mRNA expression did not differ between AD and control 
brains, but there were regionally discrete losses of the intensely expressing cells in the hippocampus. It 
is important to note that the reductions in binding did not correlate with or localise to areas showing 
histopathology (i.e. overall tissue quality or stainings for neuritic plaques and NFTs). Furthermore, 
reduced [3H]CP 55,940 binding was associated with increasing age and with other forms of cortical 
pathology. Thus, reductions in CB1/CB2 receptor expression appeared related to generalised aging 
and/or disease process and were not selectively associated with AD. 
These findings could not be replicated by follow up investigations. For example, Ramirez and 
coworkers detected CB1 and CB2 receptor expression together with markers of microglia activation in 
senile plaques in AD patients and that CB1-positive neurons were greatly reduced in areas of microglia 
activation (no change to CB2 expression) (Ramirez et al., 2005). In line with this, immunoblotting for 
CB1 receptors in postmortem cortical brain tissues (Brodmann area 10) from a cohort of 
neuropathologically confirmed AD patients and age-matched controls revealed reduced CB1 expression 
in AD brains, which was consistent with the loss of pyramidal cortical neurons in which these receptors 
are substantially expressed. A correlation between reduced CB1 expression and hypophagia was found, 
supporting the idea of a potential use of receptor agonists or cannabis sativa-derived cannabinoids in 
the management of AD-associated eating disorders (Solas et al., 2013). 
Another study analysed the expression of not only CB1 and CB2 receptors and also of FAAH in 
hippocampus and entorhinal cortex sections from postmortem brains of AD patients using 
immunohistochemistry (Benito et al., 2003). FAAH expression was increased in neuritic plaque-
associated astrocytes whereas CB2 receptors were abundantly and selectively overexpressed in 
activated microglia. Supporting this finding is another study reporting elevated levels of CB2 receptors 
in postmortem cortical brain tissues of AD patients. The elevated expression did not correlate with 
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cognitive status but two relevant AD markers, i.e. Aβ42 levels and and senile plaque manifestation 
(Solas et al., 2013). It can be postulated that CB2 receptors might be modulators of the inflammatory 
response associated with neurodegenerative processes and therefore presents a possible target for new 
therapeutic approaches. Importantly, the expression of CB1 receptors was not affected by AD. In line 
with Benito et al (2003) is a more recent study applying semi-quantitative (immunoblotting) and 
quantitative (radioligand binding) assessments to confirm that CB1 receptor levels were unchanged in 
AD in several brain regions (i.e. frontal cortex, anterior cingulate gyrus, hippocampus, and caudate 
nucleus) (Lee et al., 2010). Finally, comparative protein profiling and quantitative morphometry 
showed that overall CB1 protein levels in the hippocampi of AD patients remained unchanged relative 
to age-matched controls, and that CB1-positive presynapses engulfed Aβ-containing senile plaques 
(Mulder et al., 2011). Lee and coworkers commented on the limitations of their study design regarding 
neuroanatomical resolution (i.e. no subregion analyses were carried out), which did not allow the 
detection of subtle CB1 expresssion changes in specific cytoarchitectural or neuroanatomical domains. 
Furthermore, the functional status of CB1 receptors was not considered, which might be important, as 
Ramirez and coworkers found elevated nitration of both CB1 and CB2 protein in AD brains (Ramirez et 
al., 2005). It is interesting that a correlation was found between frontal cortical CB1 immunoreactivity 
and cognitive scores (i.e. MMSE and CAMCOG) assessed within a year before death in the AD patient 
group suggesting that CB1 receptors are intact in AD and may play a role in preserving cognitive 
function (Lee et al., 2010). However, a more recent study using immunoblotting could not replicate this 
finding when analysing correlations between cortical CB1 expression and the cognitive status (Mini 
Mental State Examination score) of AD patients (Solas et al., 2013) (for overview on changes to the 
endocannabinoid system in AD brain see Table 3). 
The endocannabinoid system seems to be further involved in human AD pathology. In a case-control 
study, the circulating levels of plasma endocannabinoids (eCBs) were analysed and the relationship 
between eCBs and TNF-α was explored in elderly control subjects and AD patients. In comparison 
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with controls, there were no significant differences in measured AEA or 2-AG concentrations in 
plasma samples from patients with AD. Furthermore, endocannabinoid levels in the CSF were not 
correlated to cognitive performance in healthy controls at risk for AD. In pooled plasma samples, an 
inverse correlation was observed between plasma levels of 2-AG (but not AEA) and TNF-α, although 
the levels of TNF-α were very low (Koppel et al., 2009). Further longitudinal studies will be required 
to conclusively assess the impact of progressive AD pathology on circulating endocannabinoid levels. 
Another study found increased hippocampal protein concentrations for the 2-AG synthesizing enzyme 
DAGL-α/β in brain tissue of patients with definite Alzheimer’s (Braak stage VI). In particular, DAGL-
β expression was found in microglia accumulating near senile plaques and apposing CB1-positive 
presynapses. Furthermore, microglia, expressing 2-AG-degrading enzymes (i.e. ABHD6 and MGL) 
began to surround senile plaques in brain tissue of patients with probable AD (Braak stage III) (Mulder 
et al., 2011). Interestingly, ABHD6 expression ceased in NFT-bearing pyramidal cells, whereas 
pyramidal cells containing hyperphosphorylated tau retained MGL expression (although at levels 
significantly lower than in neurons lacking NFT pathology). Finally, it was revealed that MGL 
recruitment to biological membranes was impaired in AD brains suggesting that disease progression 
slows the termination of 2-AG signalling.  
To conclude, the ‘endocannabinoid phenotype’ of AD brains appears to be complex and findings 
appear at times contradictory and highly dependent on the methodologies applied (e.g. type of 
polyclonal antibody, issue of cellular resolution in autoradiograpy studies, selection of mixed CB1/CB2 
versus selective receptor agonists). However, summarising the diverse findings conservatively suggests 
that alterations in the localisation, expression, and function of cannabinoid receptors occur in AD and 
may play a role in its physiopathology, thereby providing a target for therapeutic interventions.  
 
4.2 Effects of cannabinoids other than CBD on Alzheimer’s disease patients 
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Volicier’s team was the first to evaluate the therapeutic effectiveness of cannabinoids in AD (Volicer et 
al., 1997). Using a placebo-controlled crossover design, with each treatment period lasting six weeks, 
effects of dronabinol (i.e. a pharmaceutical formulation of THC) on patients with a diagnosis of 
probable AD who refused food were determined. AD patients on dronabinol treatment increased body 
weight and showed decreased severity of disturbed behaviour. This effect persisted during the placebo 
period in patients who received dronabinol first. Adverse reactions observed more commonly during 
the dronabinol treatment than during placebo periods included euphoria, somnolence and tiredness, but 
did not require discontinuation of therapy (Volicer et al., 1997).  
A second study measured the effect of dronabinol on nocturnal motor activity, as nighttime agitation 
occurs frequently in patients with dementia. Six late-stage AD patients were treated daily for two 
weeks. Dronabinol led to a reduction in nocturnal motor activity and the patients also showed improved 
Neuropsychiatric Inventory scores including for agitation, aberrant motor, and nighttime behaviours. 
No side effects were observed for dronabinol treatment (Walther et al., 2006). These authors followed 
up on their initial findings with a first randomized, controlled crossover trial of dronabinol for 
nighttime agitation in two AD patients using actigraphy as the objective measure. Administration of 
dronabinol led to reduced night time activity and strengthened circadian rhythms (Walther et al., 2011). 
Finally, another case study investigated the effects of nabilone, a synthetic cannabinoid supposedly 
mimicking the effects of THC, in the context of AD. Nabilone reduced the severity of agitation and 
resistiveness of an AD patient during evening personal care with no emergent side effects. Previous 
treatment attempts using donepezil and memantine had delivered disappointing results for this patient 
(Passmore, 2008). No blinded or placebo studies have been conducted to date. 
 
5. The future of CBD in Alzheimer’s disease therapy 
To consider CBD as a novel therapeutic option for AD naturally requires an assessment of how well 
humans tolerate CBD and what potential side effects might have to be expected. CBD has been 
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described as being non-toxic and non-cataleptic, with no impact on food intake or physiological 
parameters such as heart rate, blood pressure and body temperature and no role in psychomotor or 
psychological functions. Chronic CBD use and high doses of up to 1,500 mg/day (orally) or 30 mg i.v. 
are well tolerated in humans. However, some studies report that CBD can inhibit hepatic drug 
metabolism, be immunosuppressive, induce lymphocyte apoptosis in vitro, and decrease fertilisation 
capacity and the activity of p-glycoprotein and other drug transporters [reviewed in depth in 
(Bergamaschi et al., 2011)]. Importantly, long-term safety studies are missing to this date and the effect 
of CBD in particular in the elderly has not been assessed at all. Drug-drug interactions have not been 
evaluated in any detail either. However, it is known that CBD has an inhibiting effect on CYP 
isozymes, primarily CYP2C and CYP3A classes of isozymes. Thus, CBD could potentially impact on 
antiepileptic medication, as e.g. valproate and clobazam are metabolised via these isozymes. In 
conclusion, further studies are needed to clarify these potential in vitro and in vivo side effects before 
CBD can be trialled clinically [for a detailed overview of CBD safety in vitro and in vivo, both for 
rodents and humans, see (Bergamaschi et al., 2011): Tables 1 and 2; for side effects of CBD in vitro 
and in vivo, for rodents, monkeys and humans see Tables 3 and 4]. 
It will also be necessary to work out the best possible administration route for CBD to achieve 
clinically effective plasma and brain concentration routes. Some initial studies have been completed in 
this regard using rodent models (Deiana et al., 2012) but recent focus has shifted to assessing different 
delivery methods for cannabinoids in humans. CBD has been delivered orally in an oil-based capsule in 
some human trials. But because of the low water solubility of CBD, oral cannabinoid administration 
can result in slow and erratic absorption. Furthermore, and as discussed earlier, CBD is barely absorbed 
after oral administration (and absorption rates can be highly variable): bioavailability from oral 
delivery has been estimated to be as low as 6% due to significant first-pass metabolism in the liver 
(Mechoulam et al., 2002, Devinsky et al., 2014). Smoking and intravenous administration of 
cannabinoids both produce reliable and similar pharmacokinetic profiles. However, smoking carries 
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toxic risks and loss of active drug by combustion. An alternate method is intrapulmonary 
administration of cannabinoids via vaporisation, which is regarded as an effective mode of delivery 
since it results in fast onset of action and high systemic bioavailability and avoids risks associated with 
smoking and the formation of pyrolytic toxic compounds as a result of combustion (Solowij et al., 
2014). However, this delivery method is limited by the need for specialised equipment and patient 
cooperation with the administration method (Devinsky et al., 2014). The combined CBD+THC product 
Sativex® is administered as a oromucosal spray and appears to be safe and effective (Wade et al., 
2010). The bioavailability achieved by oralmucosal delivery appears to be similar to the oral route but 
less variable. Finally, transdermal approaches have also been investigated, but due to CBD’s high 
lipophilicity, special ethosomal delivery systems would be required to prevent drug accumulation in the 
skin, which are impractical and costly (Lodzki et al., 2003, Devinsky et al., 2014). 
 
5.1 CBD+THC combination treatment strategy 
It would be beyond the focus of this review to discuss the potential of combined CBD+THC treatment 
for AD therapy although recent evidence suggests that such a combination therapy might provide the 
‘best’ AD pathology counteracting properties of cannabinoids without the known detrimental effects of 
pure THC treatment (i.e. by blocking those effects via CBD co-treatment). However, the nature of the 
interactive relationship between THC and CBD appears very complex and the evidence provided in the 
literature to date is inconclusive if not contradictory [i.e. CBD blocking and/or facilitiating THC 
effects; e.g. (Karniol et al., 1974, Varvel et al., 2006, Klein et al., 2011); comprehensively reviewed in 
(McPartland et al., 2015)]. Reviewing this growing body of literature, it is important to pay close 
attention to the timing of CBD versus THC intake, the CBD:THC ratio and the route of administration. 
CBD can increase the potency of THC by pharmacokinetic interaction if CBD is administrated before 
THC, or a pharmacodynamic interaction may occur when both cannabinoids are taken together, mainly 
at a high dose ratio of CBD:THC [reviewed in (Bergamaschi et al., 2011)]. 
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It should be emphasized here that THC alone increases heart rate and change blood pressure, which 
may have serious consequences in people with heart disease (Jones, 2002). Furthermore, THC impacts 
on the risk to develop psychosis, although this effect is predominantly seen after long-term adolescent 
THC/cannabis abuse and mostly in people with a genetic predisposition for psychosis (Arnold et al., 
2012). Long-term use of THC can also cause the development of cannabis dependency, a growing 
problem in Western society. Finally, the negative effects of THC on cognitive abilities seem to be 
reversible after abstinence, except in heavy cannabis users (Bolla et al., 2002). In this context it is 
important to realise that there are no systematic data available determining the physiological and 
psychological effects of long-term THC treatment in the elderly population to date [reviewed in 
(Grotenhermen, 2007)].  
 
6. Concluding remarks 
AD is the most common form of dementia (i.e. around 70% of all dementia cases) and it is predicted 
that AD will affect 1 in 85 people globally by 2050. For example, over 300,000 Australians are 
currently affected by dementia at an estimated cost of $6.6 billion per annum, with the numbers 
expected to grow to >700,000 by 2050. Considering the looming burden of AD, treatments that could 
delay or even prevent the onset of AD would offer tremendous public health benefits. Unfortunately, 
current therapeutic options are limited to modest symptomatic relief, without preventing disease 
progression. The studies reviewed in this paper suggest that CBD could well provide symptomatic 
relief and/or prevent disease progression for AD patients. However, a more systematic and in depth 
characteristation of CBD in vivo, using established rodent models, is required to understand the full 
consequendes of long-term CBD treatment and to analyse potential side effects of CBD in an aging 
organism. Once those data are available, the translation of this preclinical work could be realized very 
quickly as CBD is readily available and appears safe for human use. In fact, a number of countries (e.g. 
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Canada and Germany) have already approved CBD-containing products for the treatment of pain and 
inflammation in multiple sclerosis patients. 
Such research would be very timely as it also falls within existing and developing federal regulations 
concerning medical applications of cannabis and more importantly, extracts thereof, worldwide (e.g. 
Australia, Canada, and Germany). Finally, understanding the pharmacology of CBD in more detail 
including its long-term effects in the eldery will be relevant beyond research into AD therapy, as CBD 
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Full agonist at CB1 with 
neuromodulatory effects 
(Stella et al., 1997) 
N-arachidonoylethanolamine 
(AEA or anandamide) 
Agonistic properties at both 
CB1 and CB2 with effects on 
appetite, learning and memory, 
and the generation of 
motivation and pleasure 





(Paradisi et al., 
2006) (distinct 







memory in rats) 
 




pleasure in rats) 
Exocannabinoids 
Phytocannabinoids >100 constituents of Cannabis 
sativa including the main 
psychoactive component Δ9-
tetrahydrocannabinol (THC) 
and the non-psychoactive 
constituent cannabidiol (CBD); 
multitude of effects have been 
described including on pain 
sensitivity, mood, appetite, and 
cognition 
(Fellermeier et al., 
2001) 
Cannabimimetics Synthetic cannabinoids that 
mimic actions of 
phytocannabinoids such as CP 
55,940 or WIN 55,212-2 (for 




Homologues of endocannabinoids 
2-linoleoyl glycerol 
(2-LG) 
Natural ligand for CB1; 
potentiates activity of other 
endocannabinoids including 2-
AG 
(Ben-Shabat et al., 
1998) 
Palmitoylethanolamide PPAR-γ is the main target of  (Lo Verme et al., 
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(PEA) PEA, but it also has affinity to 
cannabinoid-like G-coupled 
receptors GPR55 and GPR119, 
but no affinity for CB1/CB2; it 
can enhance effects of AEA 
probably through TRPV1 
2005) (PPAR-alpha 
is main target of 
PEA) 
 
(Godlewski et al., 
2009) (affinity for 
GPR55 and 
GPR119) 





Synthesis of AEA and PEA (Okamoto et al., 
2004) 
Diacylglycerol lipase 
(DAGL) α and β 




Degradation of 2-AG (Dinh et al., 2002, 




Degradation of 2-AG (Marrs et al., 2010) 
Fatty acid amide hydrolase 
(FAAH) 
Degradation of AEA and 2-AG (Cravatt et al., 
2001) 
Main receptors for cannabinoids 
Cannabinoid receptor 1 Involved in the majority of (D'Souza, 2007, 
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(CB1) CNS effects of cannabinoids 
including psychosis and in 
immune functions 
Cabral et al., 2008) 
Cannabinoid receptor 2 
(CB2) 
Involved in immune function 
and neuroinflammatory 
responses in CNS 
(Walter et al., 2003, 
Ramirez et al., 
2005, Pacher and 
Mechoulam, 2011) 
N-arachidonyl glycine 
receptor or G-protein coupled 
receptor 18 (GPR18) 
Abnormal cannabinoid 
receptor, activation by AEA 
and phytocannabinoids (e.g. 
THC and CBD)  
(McHugh et al., 
2010, McHugh, 
2012) 
GPR55 Potential cannabinoid receptor, 
activated by both 
endocannabinoids and 
phytocannabinoids such as 
THC and CBD 
(Brown, 2007, 
McHugh et al., 
2010, Henstridge, 
2012) 
GPR119 Potential cannabinoid receptor, 
implicated in regulation of 
food intake and body weight; 
Activation by AEA 
(Brown, 2007, 
McHugh et al., 
2010) 
Table 1: Components of the endocannabinoid system (ECS) 
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Pharmacological target Effect References 
In vitro studies 
Inhibition of caspase 3 
(involved in the signalling 
pathway for CBD) 
Increased cell survival, decreased 
ROS production and lipid 
peroxidation in PC12 cells exposed 
to Aβ 
(Iuvone et al., 
2004) 
Inhibition of 
phosphorylated p38 MAP 
kinase; activation of nuclear 
factor-kB 
Inhibits nitrite production and 
iNOS protein expression in PC12 
cells exposed to Aβ 
(Esposito et al., 
2006b) 
Rescue of Wnt/β-catenin 
pathway 
Rescues Aβ-induced toxicity and 
inhibits tau protein 
hyperphosphorylation in PC12 cells 
exposed to Aβ 
(Esposito et al., 
2006a) 
NMDA, AMPA and kainate 
receptors 
Reduction of glutamate-induced 
toxicity in primary cortical neurons 
(Hampson et al., 
1998) 
Activation of PPAR-γ Induced ubiquitination of APP and 
decreased Aβ production in APP-
expressing human neuroblastoma 
cells 
(Scuderi et al., 
2014) 
In vivo studies   
Glial pathways Reduction in interleukin-1β, iNOS 
expression and subsequent NO 
release in Aβ-injected mice 
(Esposito et al., 
2007) 
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Microglia Induced microglial migration, 
suppression of interleukin-6 and 
prevented spatial memory deficits  
in Aβ-injected mice 
(Martin-Moreno 
et al., 2011) 
Indirect activation of CB1 
receptor  
Increased adult neurogenesis in 
CB1 receptor deficient mice with no 
effect on cognition in WT mice 
(Wolf et al., 
2010) 
Activation of PPAR-γ Induced hippocampal neurogenesis 
and reduced reactive gliosis in Aβ-
injected rats 
(Esposito et al., 
2011) 
Inverse CB2 receptor 
agonism 
Antagonises CB2 receptor agonists 
in WT mice 
(Thomas et al., 
2007) 
Table 2: Pharmacological targets of CBD 
  
 58 
Component of ECS AD-relevant effects References 
CB1 receptors No differences were reported for 
receptor expression, distribution or 
availability  in cortex or hippocampus 
of AD patients 
(Benito et al., 2003, Lee 
et al., 2010, Mulder et 
al., 2011, Ahmad et al., 
2014) 
 CB1 receptor expression in AD was 
comparable to normal ageing 
(Westlake et al., 1994) 
 CB1 receptors reported to be rduced in 
cortical areas and neurons away from 
senile plaques 
(Ramirez et al., 2005, 
Solas et al., 2013) 
 CB1 receptor expression was reported to 
not correlate with any AD biomarkers 
or cognitive deficits 
(Solas et al., 2013) 
 Nitrosylated in AD brain allowing the 
potential for impaired coupling of 
receptors 
(Ramirez et al., 2005) 
CB2 receptors CB2 receptor expression reported to 
correlate with Aβ42 levels and plaque 
deposition but not cognitive changes 
(Solas et al., 2013) 
 CB2 receptor expression reported to be 
abundantly and selectively 
overexpressed in microglia 
(Benito et al., 2003) 
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 Nitrosylated in AD brain allowing the 
potential for impaired coupling of 
receptors 
(Ramirez et al., 2005) 
FAAH Significantly increased FAAH 
concentration in neuritic plaque-
associated glia and in peripheral blood 
mononuclear cells of AD patients 
(Benito et al., 2003, 
D'Addario et al., 2012) 
 No changes in FAAH protein content in 
hippocampal homogenates 
(Mulder et al., 2011, 
Pascual et al., 2014) 
 Decreased FAAH activity in frontal 
cortex of AD patients, which is 
mimicked by the addition of Aβ40 
peptide to control brain samples 
(Pascual et al., 2014) 
AEA No differences reported for AEA 
plasma concentration in AD patients 
compared to control subjects 
(Koppel et al., 2009) 
 Lower AEA concentration in AD brain 
(midfrontal and temporal cortices) 
compared to control and inversely 
correlated with Aβ42 peptide and 
severity of cognitive deficits 
(Jung et al., 2012) 
 Increased degradation of AEA in AD 
frontal cortex compared to controls 
(Pascual et al., 2014) 
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2-AG No differences reported for 2-AG 
plasma concentration in AD patients 
compared to control subjects 
(Koppel et al., 2009) 
 Altered 2-AG signalling during late 
stages of AD due to combination of 
impared MAGL recruitment and 
increased DAGL concentration 
(Mulder et al., 2011) 
Table 3: The endocannabinoid system and Alzheimer’s disease 
 
